Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)

CAPS Rating: 5 out of 5

The Company is engaged in the discovery and development of synthetic DNA and RNA-based compounds for the treatment of cancer, infectious diseases, autoimmune diseases, and asthma/allergies, and for use as vaccine adjuvants.

Recs

0
Player Avatar chicachick (71.74) Submitted: 10/12/2010 3:48:03 PM : Outperform Start Price: $3.01 IDRA Score: -79.54

Bravobevo

Featured Broker Partners


Advertisement